Combined Modalities Improve Survival in Stage III Inoperable NSCLC
This study tested the efficacy of singular and combined treatment modalities on survival in patients with inoperable, locally advanced non-small cell lung cancer (≥70 years).
Lung Cancer
Potential Med Errors Prompt FDA Action on Vinca Alkaloid Labeling
Chemotherapy agents such as vincristine sulfate injection, vinblastine sulfate injection, and vinorelbine tartrate injection should only be prepared in IV infusion bags.
MPR Weekly Dose Podcast Episode 63
On the first MPR pod of 2021 we cover the latest COVID-19 vaccine news including admin. scheduling and production; A diagnostics test that may be giving false negative results; Bristol Myers Squibb withdraws an indication for Opdivo; And experts vote on the best diets for 2021.
Tiragolumab Gets Breakthrough Therapy Status for PD-L1-High NSCLC
Tiragolumab is a monoclonal antibody that works by binding to TIGIT, a protein receptor on immune cells, and blocking its interaction with the poliovirus receptor.
New Drugs Approved in 2020
Visit our New Drug Products page to stay up-to-date on the latest drug approvals.
Opdivo No Longer FDA-Approved for Small Cell Lung Cancer
In 2018, the FDA granted accelerated approval to Opdivo for SCLC based on data from the phase 1/2 CheckMate -032 trial.
Lorlatinib Under Review for Previously Untreated ALK-Positive NSCLC
The sNDA is supported by data from the phase 3 CROWN study comparing lorlatinib to Xalkori in 296 adults with advanced ALK-positive NSCLC.
Tagrisso Approved as Adjuvant Therapy for Early-Stage EGFR-Mutant NSCLC
The approval was based on data from the double-blind, placebo-controlled phase 3 ADAURA study.
New Dosing Option Approved for Imfinzi in NSCLC, Bladder Cancer
The approval was based on data from several clinical trials, including the phase 3 PACIFIC trial and the phase 3 CASPIAN trial.
Lorlatinib Superior to Crizotinib for ALK-Positive NSCLC
Interim analysis shows risk for disease progression or death lower for first-line therapy with lorlatinib versus crizotinib
